Drugs Approved in China but Not in the US or EU (2026)
Why this list matters
There is a specific category of patient who is poorly served by every medical tourism site: someone whose doctor has told them there is nothing more available in their country.
For that patient, the question is not “is China cheaper.” It is “is there anything in China that does not exist where I live.”
For a small but real number of conditions, the answer is yes. This article lists the categories where that is true, as of October 2026.
Two caveats before you read on:
- Availability in China does not mean it is right for you. A drug being approved is not a treatment recommendation. Only your physician can assess that.
- Getting these drugs as a foreign patient is a process, not a purchase. Not every hospital can prescribe every drug, and some are restricted to specific settings. We explain the pathways below.
The structural reason this list exists
China’s drug approval system changed substantially in 2015–2020. Before that, foreign drugs arrived in China years late. Now the reverse has started to happen in a few areas:
- Domestic biotech companies now develop drugs that get approved in China first, because that is where their trials ran
- The NMPA (China’s regulator) has accelerated review for drugs addressing unmet need
- Some Chinese-origin molecules have no approved equivalent in the US or EU at all
This is a genuine change, not marketing. It is also narrow — the list below is short, and it is concentrated in oncology, hematology, and a few other areas.
Category 1: Chinese-origin oncology drugs with no Western equivalent
Ivonescimab (依沃西单抗, brand: 依达方)
- What it is: A bispecific antibody targeting PD-1 and VEGF, developed by Akeso (康方生物).
- Status in China: Approved. Notably, in a head-to-head Phase 3 trial against pembrolizumab (Keytruda) in PD-L1-positive advanced NSCLC, it reportedly showed a progression-free survival benefit.
- Status in US/EU: Not approved as of October 2026. A licensing deal with Summit Therapeutics has trials running, but approval is not in place.
- Why it matters: This is the clearest example of a drug available in China and unavailable in the West — and one of the few cases where a Chinese-origin drug has beaten a global standard of care in a head-to-head trial.
We are not stating that this drug is right for any particular patient. We are stating that it is approved in China and not elsewhere.
Other Chinese-origin approvals in oncology have accumulated rapidly since 2020. A detailed list is beyond one article; the pattern is that domestic PD-1/PD-L1 inhibitors, CAR-T products, and several targeted kinase inhibitors were approved in China before or without Western approval.
Category 2: CAR-T therapy — available, and dramatically cheaper
CAR-T is approved in the US and EU. It is on this list for a different reason: cost and accessibility.
| China | United States | |
|---|---|---|
| Approved products | Multiple domestic CAR-T products | Multiple |
| Cost per treatment | USD 40,000–80,000 | USD 400,000–600,000 |
| Wait/access | Direct self-pay access at designated centers | Insurance authorization often required |
Multiple Chinese hospitals have treated foreign patients with CAR-T. One Shanghai provider reported treating roughly 30 foreign patients for CAR-T since late 2024.
Important limitations:
- CAR-T is not a general-purpose cancer treatment. It applies to specific hematologic malignancies (certain lymphomas, leukemias, myeloma).
- It carries serious risks, including cytokine release syndrome. This is not a procedure to travel for casually.
- Not every hospital offering CAR-T accepts foreign patients.
Category 3: Hainan Boao Lecheng — a legal pathway to unapproved drugs
This is the most under-discussed mechanism, and it is the reason China is worth considering for some patients even when a drug is not approved in mainland China.
What Lecheng is: The Boao Lecheng International Medical Tourism Pilot Zone in Hainan. It is the only place in China where drugs and devices approved abroad but not yet in mainland China can be used legally.
How it works:
- A drug approved by the FDA, EMA, or Japan’s PMDA but not by the NMPA can be brought into Lecheng
- It must be used within designated Lecheng institutions
- Patients can take a limited quantity out of the zone for personal use
- Approval timelines within the zone have been compressed dramatically (reported as low as 1.6 days for some applications)
Scale (2025): Lecheng hosted roughly 9,344 inbound medical visits from 14 countries, plus 865,300 total medical tourism visits.
Why this matters for a foreign patient: If the drug you need is approved in the US or Europe but not yet in China, Lecheng is a legal pathway to access it inside China. It does not help if the drug is unavailable everywhere.
Category 4: Areas where China’s volume creates capability
Some treatments are not “unique to China” but China performs more of them than anywhere else, which affects both cost and operator experience.
| Area | Why China is notable |
|---|---|
| Cryoablation / NanoKnife for inoperable tumors | Guangzhou’s Fuda Cancer Hospital reports world-leading case volume |
| Proton and heavy ion therapy | Multiple centers; cost ~USD 30,000–55,000 vs significantly higher elsewhere |
| Robotic surgery | Very high procedure volumes at major centers |
| Liver surgery and liver transplant | High volume, including living-donor programs |
| Thalassemia and hematologic care | One Beijing/Shanghai group reports 97% thalassemia survival |
Volume is not the same as superiority. But for complex procedures, operator experience is a real variable, and China’s case volumes in several areas are genuinely among the world’s highest.
The honest limitations
This list is short, and it should be read alongside what China cannot do.
What China generally does not offer:
- Broad access to drugs that are unapproved everywhere (nor should it)
- The same depth of rare-disease expertise as a few US/EU centers, in specific conditions
- Continuity of care if you return home — your local doctor may not be able to monitor a China-only regimen
- Easy insurance coverage — most foreign patients pay out of pocket
What goes wrong for patients pursuing this:
- Finding a hospital that can prescribe the drug, versus one that says it can
- Discovering the drug requires a specific diagnostic marker you do not have
- Paying for travel before confirming eligibility
- No follow-up plan for after return
We are not claiming any of these drugs will help any specific patient. A drug existing is not the same as a drug working for you.
Questions to ask before pursuing any of this
If you are considering travel for a China-only or China-cheaper therapy, get written answers to these:
- Is the drug approved in China for my specific indication? (Not a similar one.)
- Is there published trial data for that indication, or only for another?
- Does the hospital accept foreign patients for this specific treatment?
- What is the total cost, itemized, including pre-treatment workup?
- What happens if I have a serious adverse event in China?
- Who monitors me after I go home, and can they access the drug?
- What is the plan B if I turn out not to be eligible?
Any provider who cannot answer all seven in writing is not ready to take your case.
What we do
We help patients from Southeast Asia and the Middle East research medical options in China — including cases where the relevant question is availability, not price.
We charge you a flat fee. We take no money from hospitals or drug companies. If a treatment is not right for you, our revenue does not change — but our reputation does, which is why we say so.
We do not give medical advice, we do not prescribe, and we do not decide whether a treatment is appropriate. That is your physician’s role.
Download the current list
We maintain a structured list of China-approved therapies with no equivalent abroad — including approval dates, indications, and which hospitals can prescribe them as of the most recent quarter.
[Get the 2026 China-Only Therapies List →]
This article is current as of October 2026 and is informational only. It is not medical advice and does not recommend any treatment for any individual. Drug approval status changes; verify with the relevant regulator and your physician. We are not affiliated with any pharmaceutical manufacturer or hospital named above.